Here are the 10-K annual reports from Cytek Biosciences, Inc. (CTKB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow CTKB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTKB filings page.
Cytek Biosciences reports 2025 results and outlines its strategy as a leading cell analysis solutions provider built around its patented Full Spectrum Profiling (FSP) flow cytometry technology. The company sells Aurora, Northern Lights, Aurora Evo and Aurora CS instruments, reagents, software and services to pharma, biotech, CROs and academic labs worldwide.
Revenue was $201.5 million in 2025, up slightly from $200.5 million in 2024 and $193.0 million in 2023, while the net loss widened to $66.5 million from $6.0 million in 2024 and $12.1 million in 2023. Cash, cash equivalents, restricted cash and short-term investments totaled $261.5 million as of December 31, 2025.
The filing highlights new products such as the Aurora Evo system, Enhanced Small Particle detection, the Muse Micro analyzer and expansion of manufacturing in China and Singapore. Cytek emphasizes recurring consumables, software ecosystems like Cytek Cloud, clinical applications, global scale and an intellectual property portfolio protecting its FSP platform.